Search

Your search keyword '"Pizzocaro G"' showing total 13 results
Start Over Author "Pizzocaro G" Publisher elsevier b.v.
13 results on '"Pizzocaro G"'

3. 57 Neo-adjuvant and adjuvant combination of a taxane plus cisplatin and 5-fluorouracil in patients undergoing lymph-node dissection for nodal metastases from squamous cell carcinoma (SCC) of the penis: Is there an indication for a recommendable use?

Author

Nicolai, N., Sangalli, L.M., Necchi, A., Giannatempo, P., Paganoni, A.M., Colecchia, M., Piva, L., Catanzaro, M., Biasoni, D., Stagni, S., Torelli, T., Raggi, D., Faré, E., Crestani, A., Pizzocaro, G., and Salvioni, R.

Published
2014
Full Text
View/download PDF

10. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes†.

Author

Necchi, A., Nicolai, N., Mariani, L., Raggi, D., Farè, E., Giannatempo, P., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Milani, A., Piva, L., Pizzocaro, G., Gianni, A. M., and Salvioni, R.

Subjects
*CISPLATIN, *ETOPOSIDE, *CYCLOPHOSPHAMIDE, *SALVAGE therapy, *GERM cell tumors, *GLUCOSIDES, *PODOPHYLLOTOXIN, *THERAPEUTICS
Abstract

Background Since 1985, we introduced a modified combination of etoposide, ifosfamide, and cisplatin (PEI) as second-line therapy of adult male germ cell tumors with the aim to reduce toxic effect while maintaining efficacy over the original regimen. Patients and Methods Patients received four cycles of ifosfamide at 2.5 g/m2 on days 1–2, etoposide, and cisplatin at 100 and 33 mg/m2, respectively, on days 3–5 every 21 days, followed by surgery. Results were stratified according to the International Germ Cell Consensus Classification Group-2 (IGCCCG-2). Results From February 1985 to January 2012, 189 patients were treated. 72.6% were IGCCCG-2 intermediate-to-very high risk. Thirty-five patients (18.5%) had a complete response, 67 (35.4%) a marker normalization (PRm−). Median follow-up was 122.1 months (inter-quartile range [IQR]: 71.4–232.0). Two-year progression-free and 5-year overall survival were 34.3% [95% confidence interval (CI) 28.1% to 41.9%] and 42.1% (95% CI 35.3% to 50.2%), respectively. Survival estimates compared favorably with those obtained by conventional dose chemotherapy (CDCT) regimens in each prognostic category. 70.4% of grade 3–4 neutropenia (25.5% febrile neutropenia), 48.1% thrombocytopenia, 21.2% anemia, 3.2% neurotoxic effect, and no severe renal toxic effect were recorded. Conclusion Dose-modified Italian PEI should be considered as an appropriate benchmark for CDCT in the first salvage setting. [ABSTRACT FROM PUBLISHER]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results